Andrew Balo

2019

In 2019, Andrew Balo earned a total compensation of $3M as EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development at DexCom, a 5% decrease compared to previous year.

Compensation breakdown

Bonus$7,500
Non-Equity Incentive Plan$461,160
Salary$384,300
Stock Awards$2,146,723
Other$23,007
Total$3,022,690

Balo received $2.1M in stock awards, accounting for 71% of the total pay in 2019.

Balo also received $7.5K in bonus, $461.2K in non-equity incentive plan, $384.3K in salary and $23K in other compensation.

Rankings

In 2019, Andrew Balo's compensation ranked 4,055th out of 13,971 executives tracked by ExecPay. In other words, Balo earned more than 71.0% of executives.

ClassificationRankingPercentile
All
4,055
out of 13,971
71st
Division
Manufacturing
1,465
out of 5,692
74th
Major group
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks
202
out of 832
76th
Industry group
Surgical, Medical, And Dental Instruments And Supplies
115
out of 535
79th
Industry
Surgical and Medical Instruments and Apparatus
71
out of 350
80th

Pay ratio

Andrew Balo's Pay$3,022,690
Median Employee's Pay$94,523
Pay Ratio

32

to 1

In 2019, the annual total compensation of Andrew Balo was $3,022,690.

The annual total compensation of the median employee at DexCom was $94,523.

The ratio of Andrew Balo's pay to the pay of median employee was therefore 32 to one.

Source: SEC filing on April 10, 2020.

Balo's colleagues

We found four more compensation records of executives who worked with Andrew Balo at DexCom in 2019.

2019

Kevin Sayer

DexCom

Chief Executive Officer

2019

Quentin Blackford

DexCom

Chief Financial Officer

2019

Richard Doubleday

DexCom

EVP, Chief Commercial Officer

2019

Steven Pacelli

DexCom

EVP, Strategy and Corporate Development

News

You may also like